Showing 3461-3470 of 5661 results for "".
- ADapt Study: Lebrikizumab Improves Skin and Quality of Life in ADhttps://practicaldermatology.com/news/study-lebrikizumab-improves-skin-and-quality-life-ad/2470753/Results from the phase 3b ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated lebrikizumab (LEB) improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis (AD) in whom dupilumab (DUPI) was
- Psoriasis Linked with Education, Mood Disorders: Studyhttps://practicaldermatology.com/news/psoriasis-tied-education-and-mood-disorders-study/2468759/A new genetic study has identified six previously unreported loci associated with psoriasis, emphasizing its genetic complexity and links to socioeconomic and mental health factors. The analysis included data from 925,649 individuals across the FinnGen, Estonian Biobank, and UK Biobank, ma
- Early-Onset AD Linked to Higher Rates of Atopic Marchhttps://practicaldermatology.com/news/early-onset-ad-linked-higher-rates-atopic-march/2468704/Early-onset atopic dermatitis (AD) is associated with higher rates of developing atopic march conditions compared to controls, according to new research in the Journal of the American Academy of Dermatology. “Particular attention should be paid towards risk factors and atopic marc
- Study Links Severe AD With Need for Surgery in Glaucoma Patientshttps://practicaldermatology.com/news/study-links-severe-ad-need-surgery-glaucoma-patients/2468562/Patients suffering from both severe atopic dermatitis (AD) and glaucoma are increasingly likely to need surgical intervention for the glaucoma depending on the severity of their AD, according to a new Journal of Glaucoma study. “Association of Atopic Dermatitis and Risk of Glaucoma Surgery
- First Patient Dosed in Phase 3 Trial of Rapamycin for Microcystic LMshttps://practicaldermatology.com/news/first-patient-dosed-phase-3-trial-rapamycin-microcystic-lms/2468559/Palvella Therapeutics, Inc. announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the safety and efficacy of its 3.9% rapamycin anhydrous gel, QTORIN™ rapamycin, for the treatment of microcystic lymphatic malformations (LMs). "Micro
- 3 Oral JAK Inhibitors for Vitiligo 'Running to the Finish Line'https://practicaldermatology.com/news/3-oral-jak-inhibitors-vitiligo-running-finish-line/2468487/Recent data supporting the use of topical ruxolitinib and oral Janus kinase (JAK) inhibitors for treating vitiligo were presented by Dr. Seemal Desai and Dr. Larry Eichenfield at the 44th Annual Fall Clinical Dermatology Conference. In the TRuE-V1 and TRuE-V2 studies, for all body regions
- Atopic Dermatitis Linked to Peripheral Vascular Diseasehttps://practicaldermatology.com/news/atopic-dermatitis-linked-peripheral-vascular-disease/2468444/People with atopic dermatitis (AD) are almost twice as likely to develop peripheral vascular disease (PVD), Yale School of Medicine researchers found in a new study. “Associated between atopic dermatitis and peripheral vascular disease: a cross-sectional study in the All of Us Research Pro
- FDA Approves Up To 3 Tubes of Ameluz Topical Gel, 10% In 1 Treatmenthttps://practicaldermatology.com/news/fda-approves-3-tubes-ameluz-topical-gel-10-1-treatment/2468368/The US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) to increase the maximally approved dosage from one to three tubes of Biofrontera Inc.’s Ameluz® per treatment, the company announced. Biofrontera Inc. said in a press release that the approval
- Study: Excessive Sweating Linked to Sensitive Skinhttps://practicaldermatology.com/news/study-excessive-sweating-linked-sensitive-skin/2468351/A new study indicates a significant connection between primary hyperhidrosis, a condition of excessive sweating, and sensitive skin, where skin overreacts to stimuli like sweat and stress. The study was led by Practical Dermatology Editorial Board member Adam Friedman, MD, FAAD, chair of d
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc